Castle Biosciences ( CSTL ) is on the Move, Here's Why the Trend Could be Sustainable
Castle Biosciences (CSTL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
5 Stocks With Recent Price Strength Amid Wall Street Volatility
CSTL, IDN, PANL, FSRL and PRM are showing sharp price strength amid renewed Wall Street volatility.
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
AVDL's board calls Lundbeck's higher $23-per-share bid superior to its Alkermes deal, triggering a critical five-day response window.
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
Castle earns 4 Top Workplaces Awards-Houston Top Workplace plus 3 Culture Excellence Awards-bringing their 2025 total Top Workplaces Awards to ...
Forget the Fed, Bet on These 4 Stocks With Increasing Cash Flows
Four rising cash-flow stocks, including PRM, TILE, CSTL and GLDD, stand out with upgraded earnings estimates and strong VGM scores.
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
Castle Biosciences' executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on 12/2/25 at 1:10pm ET ...
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. ( NASDAQ:CSTL ) , a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 37th ...
4 Stocks With Recent Price Strength to Enhance Your Portfolio
Four stocks, CSTL, PRM, SABK and ATRO show recent gains, signaling potential momentum plays for investors in 2025.
Recent Price Trend in Castle Biosciences ( CSTL ) is Your Friend, Here's Why
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Why Castle Biosciences' Rally Might Just Be Getting Started - Castle Biosciences ( NASDAQ:CSTL )
Castle Biosciences ( NASDAQ:CSTL ) rallied more than 20% after delivering a strong Q3 performance. When analyzed through the lens of the Adhishthana Principles, the stock shows clear signs of momentum building. Here's why the current setup looks promising and what lies ahead.
AMD To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday - Advanced Micro Devices ( NASDAQ:AMD ) , Archer-Daniels-Midland ( NYSE:ADM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised Advanced Micro Devices, Inc. ( NASDAQ:AMD ) price target from $240 to $280.
Castle Biosciences, Inc. ( CSTL ) Reports Q3 Loss, Tops Revenue Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of +94.12% and +16.47%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. ( NASDAQ:CSTL ) , a company improving health through innovative tests that guide patient care, today announced the launch of AdvanceAD-Tx™, a gene expression profile ( GEP ) test designed to guide systemic treatment ...
Forget Profit, Pick These 4 Stocks With Increasing Cash Flows
Amid earnings buzz, stocks like RadNet, Mission Produce, Castle Biosciences and FreightCar America stand out for their rising cash flows and resilience.
Agios Pharmaceuticals ( AGIO ) Reports Q3 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +7.77% and +27.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences Holdings, Inc. ( HRMY ) Earnings Expected to Grow: Should You Buy?
Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences to Participate in Upcoming Investor Conferences - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. ( NASDAQ:CSTL ) , a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens 27th Annual ...
Analysts Estimate Castle Biosciences, Inc. ( CSTL ) to Report a Decline in Earnings: What to Look Out for
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, Oct. 26, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. ( NASDAQ:CSTL ) , a company improving health through innovative tests that guide patient care, today announced new data demonstrating that its TissueCypher® Barrett's Esophagus test can provide risk insights beyond ...
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus
Castle announced new data on its TissueCypher® Barrett's Esophagus test being presented at ACG 2025.
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference - Castle Biosciences ( NASDAQ:CSTL )
This new histological subtype data confirms DecisionDx-Melanoma's clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test
New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
How Much Upside is Left in Castle Biosciences ( CSTL ) ? Wall Street Analysts Think 50.08%
The consensus price target hints at a 50.1% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Castle Biosciences ( CSTL ) a New Strong Buy Stock
Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
Castle Biosciences will release Q3 2025 financial results and host conference call on Monday, Nov. ...
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025 - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. ( NASDAQ:CSTL ) , a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2025, ...
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
Castle Biosciences' Founder, President & CEO Derek Maetzold awarded CEO of the Year by The CEO Magazine ...
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
Castle Biosciences has been recognized as a Greater Pittsburgh Top Workplace by The ...
Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025
Castle Biosciences has been included in the inaugural 2025 America's Greatest Companies list, published by Newsweek.
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc.
New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
Castle will share new data on its TissueCypher Barrett's Esophagus test via a podium presentation on Sept. 13 at the AFS 2025 Annual Meeting.
Castle Biosciences to Participate in Upcoming Investor Conferences - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2025 Global Healthcare Conference ...
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences will participate in three investor conferences in September ...
Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday - Arteris ( NASDAQ:AIP ) , AECOM ( NYSE:ACM )
U.S. stocks were lower, with the Dow Jones index gaining around 100 points on Tuesday. Shares of Sterling Infrastructure, Inc. STRL rose sharply during Tuesday's session after the company reported better-than-expected quarterly financial results and raised its FY25 guidance.
Castle ( CSTL ) Q2 Revenue Tops Estimates
Castle Biosciences ( NASDAQ:CSTL ) , a developer of diagnostic tests supporting personalized treatment decisions in dermatology and gastroenterology, reported its second quarter 2025 results on August 4, 2025. The company significantly outperformed Wall Street expectations in Q2 2025, with GAAP ...
Castle Biosciences, Inc. ( CSTL ) Q2 Earnings and Revenues Surpass Estimates
Castle Biosciences (CSTL) delivered earnings and revenue surprises of +129.41% and +16.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for August 1st
CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.
TG Therapeutics ( TGTX ) Earnings Expected to Grow: What to Know Ahead of Q2 Release
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Castle Biosciences' executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference Aug. 12, 2025 at 12:30pm ET ...
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, July 29, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45th Annual Growth ...
Earnings Preview: Castle Biosciences, Inc. ( CSTL ) Q2 Earnings Expected to Decline
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
Castle announced that its chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal.
FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test
Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture
Castle Biosciences announced that it has earned multiple awards through the 2025 Top Workplaces program recognizing its strong company culture.
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
Castle Biosciences will release Q2 2025 financial results and host conference call on Monday, Aug. 4, 2025 at 4:30 p.m. ET ...
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 - Castle Biosciences ( NASDAQ:CSTL )
FRIENDSWOOD, Texas, July 14, 2025 ( GLOBE NEWSWIRE ) -- Castle Biosciences, Inc. CSTL, a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on ...
